Welcome to our dedicated page for Quince news (Ticker: QNCX), a resource for investors and traders seeking the latest updates and insights on Quince stock.
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company focused on rare diseases, with news flow centered on its clinical programs, scientific publications, and corporate developments. The company’s updates frequently highlight progress with its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), and its proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform.
Investors following QNCX news can expect regular announcements on the pivotal Phase 3 NEAT clinical trial of eDSP in Ataxia-Telangiectasia (A-T), including milestones such as completion of enrollment, last patient last visit, safety reviews by an independent data and safety monitoring board, and plans for topline data. Quince also issues press releases on related open label extension studies, pediatric investigational plans, and preparation for potential regulatory submissions.
Beyond trial status, Quince’s news includes peer-reviewed publications and conference presentations. Recent communications have described early-stage clinical studies of eDSP in pulmonary and inflammatory bowel disorders, population pharmacokinetic modeling in A-T, and analyses of patient-reported walking capacity in children with A-T. These items provide scientific context for the company’s approach to erythrocyte-based corticosteroid delivery.
Corporate and financial updates are another key component of QNCX coverage. The company reports quarterly financial results, financing transactions, amendments to its European Investment Bank credit facility, and strategic relationships such as its agreement with Option Care Health to support potential commercial launch of eDSP in the United States. Quince also announces participation in healthcare conferences, investor days, and rare disease summits, where management discusses development plans, regulatory strategy, and potential pipeline expansion.
This news page aggregates these clinical, scientific, regulatory, and corporate disclosures so that readers tracking Quince Therapeutics and QNCX stock can review the company’s latest rare disease developments in one place.
Quince Therapeutics, Inc. (QNCX) showcased its innovative bone-targeting platform at the Military Health System Research Symposium 2022. The company's lead compound, NOV004, exhibited potential to accelerate healing in traumatic bone injuries, reducing healing time by 50% in animal models. Quince's approach targets bone fractures directly, offering a unique solution in a market lacking FDA-approved systemic therapies for fracture repair. The company plans to advance NOV004 into Phase 1 clinical studies in 2023, focusing on osteogenesis imperfecta and other significant bone diseases.
Quince Therapeutics (NASDAQ: QNCX) presented at the ASBMR 2022, highlighting its innovative bone-targeting platform for treating spinal fusion and bone cancer. The company showcased two preclinical studies: one on NOV004, aimed at improving spinal fusion outcomes through targeted delivery, and another focusing on a radioactive conjugate for bone cancer therapy. Both approaches aim to enhance healing and patient outcomes by directly addressing bone injuries and diseases.
Quince Therapeutics (NASDAQ: QNCX) presented promising preclinical data at the 14th International Conference on Osteogenesis Imperfecta (OI 2022) regarding its novel therapeutic NOV004. The data indicates NOV004's potential to significantly enhance bone density, strength, and healing in osteogenesis imperfecta (OI). In preclinical models, a two-fold improvement in calcified bone and a three-fold increase in maximum load were documented. NOV004 is slated to enter Phase 1 clinical studies in 2023, aiming to address unmet medical needs in OI.
Quince Therapeutics, Inc. (QNCX) has announced its participation in key scientific meetings in September 2022, including the 14th International Conference on Osteogenesis Imperfecta, ASBMR 2022, and the Military Health System Research Symposium. Key presentations will focus on their novel therapies for bone diseases, including Fracture-targeted Anabolics and Improved Spinal Fusion. The company's lead candidate, NOV004, is engineered for targeted delivery to enhance bone healing and is expected to enter Phase 1 clinical studies in 2023.
Quince Therapeutics, Inc. (NASDAQ: QNCX) announced that CEO Dirk Thye will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 9:00 a.m. ET. Investors can access a live webcast on the Investor Calendar page of Quince's website. The company focuses on innovative precision therapeutics for rare diseases, with its lead compound, NOV004, aimed at treating osteogenesis imperfecta and promoting rapid bone healing. NOV004 is set to enter Phase 1 clinical trials in 2023, targeting major unmet medical needs in bone health.
Quince Therapeutics, trading under the new Nasdaq ticker symbol QNCX, announces a strategic focus on developing precision therapeutics for rare diseases. The company emphasizes its lead molecule, NOV004, a bone-targeting drug designed to address significant unmet medical needs, particularly in skeletal indications. With approximately $105 million in cash, Quince expects to fund operations into the second half of 2025. The strategic plan includes acquiring clinical-stage assets and out-licensing legacy products, enhancing its pipeline in underserved therapeutic areas.
Cortexyme, Inc. will officially change its name to Quince Therapeutics on August 1, 2022, with the ticker symbol transitioning from CRTX to QNCX on the Nasdaq Global Select Market. This change aims to reflect the company’s updated growth strategy and development pipeline, which will be detailed in an upcoming news release. The current stock certificates remain valid and require no exchange. In conjunction with the name change, Quince Therapeutics will launch a new corporate website and social media profiles on Twitter and LinkedIn, also effective August 1, 2022.